Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
A clinical trial evaluating radiomic predictors of HER2 status and response to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer, c…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen Pathology [NA]
This clinical trial update reports ongoing comparative research to evaluate the accuracy of margin interpretation in breast-conserving surge…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
A completed real-world study analyzing palbociclib in combination with aromatase inhibitors as first-line therapy for metastatic breast canc…
-
CLINICAL_TRIALS trial_result · 2025-06-19Clinical Trial Update: Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors
Clinical trial update from NINR describes characterizing fatigue in cancer patients during primary treatment and in cancer survivors; the st…
-
EMA approval · 2025-06-19EMA Authorised: Pazenir (paclitaxel) — ratiopharm GmbH
Pazenir (paclitaxel) has been authorised by EMA for use in breast cancer, with ratiopharm GmbH as the Marketing Authorisation Holder.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]
Phase III trial evaluating ESG401 for locally advanced or metastatic HR+/HER2- breast cancer; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) [Phase 3]
A Phase 3 recruitment update for CAMBRIA-2, a study of Camizestrant (AZD9833) as adjuvant endocrine therapy for ER+/HER2- early breast cance…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer [Phase 2]
This document reports a phase 2 clinical trial evaluating PCS6422 in combination with capecitabine for advanced or metastatic breast cancer,…
-
CLINICAL_TRIALS research · 2025-06-18Clinical Trial Update: Evaluation of Vaginal Microbiome as a Biomarker for the Improvement of Vaginal Health in Women With Breast Cancer, ARISE Study
Clinical trial update for the ARISE study evaluating vaginal microbiome as a biomarker for vaginal health in women with breast cancer; the s…
-
CLINICAL_TRIALS research · 2025-06-18Clinical Trial Update: Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors [NA]
This clinical trial update describes dietary and exercise interventions aimed at reducing side effects in patients with stage I-IIIa breast …
-
CLINICAL_TRIALS research · 2025-06-18Clinical Trial Update: Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
This clinical trial investigates how molecular markers relate to response to therapy and the behavior of breast cancer; the study is current…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: Mindful Eating in Breast Cancer Survivors: A Pilot Study in Türkiye [NA]
A completed pilot clinical trial in Türkiye evaluating mindful eating as a behavioral intervention for breast cancer survivors.
-
FDA approval · 2025-06-17FDA Approved: CAPECITABINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Capecitabine filed by Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies [EARLY_Phase 1]
An early-phase 1 trial evaluating a radionuclide-labeled HER2-targeting antibody for diagnostic use in HER2-positive cancers, with enrollmen…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer [EARLY_Phase 1]
An EARLY Phase 1 trial is evaluating a Gallium-68 labeled CD73-targeting PET/CT imaging probe for diagnosing breast cancer, currently recrui…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors [EARLY_Phase 1]
Early-phase PET imaging study evaluating 89Zr-labeled antibody fragments targeting HER2 in patients with malignant tumors to assess uptake a…
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: Autologous Fat Infiltration Versus General Measures as Treatment in Radiodermatitis Induced for Radiotherapy in Breast Cancer Patients [NA]
A completed clinical trial comparing autologous fat infiltration to general care for radiodermatitis in breast cancer patients undergoing ra…
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer [NA]
A completed Emory University study evaluating a mobile health intervention to improve adherence to oral chemotherapy in women with breast ca…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction [NA]
A clinical trial evaluating preoperative nicotine cessation in women with breast cancer who are recommended for reconstruction; currently re…
-
FDA approval · 2025-06-16FDA Approved: EXEMESTANE — Supplemental Application (Upsher-Smith Laboratories, Inc.)
The FDA approved a supplemental application for Exemestane submitted by Upsher-Smith Laboratories, Inc.
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer [Phase 3]
A Phase 3 trial comparing TAC versus TCX as adjuvant therapy for high-risk HER2-negative breast cancer has completed. The update does not pr…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Tolerance to Immunomodulatory Nutritional Therapy in Oncology Patients Undergoing Chemotherapy and Radiotherapy [NA]
A completed clinical trial update examining the tolerance of immunomodulatory nutritional therapy in oncology patients undergoing chemothera…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: PEMF and PEC Blocks in Mastectomy Reconstruction Patients [Phase 4]
A Phase 4 clinical trial evaluating pulsed electromagnetic field therapy (PEMF) and pectoral (PEC) nerve blocks in women undergoing mastecto…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Matrix Rotation Flap Versus Single Incision Lateral Sulcus Mammoplasty [NA]
Completed clinical trial comparing matrix rotation flap versus single-incision lateral sulcus mammoplasty for breast cancer treatment.
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients [Phase 2]
A Phase II clinical trial is evaluating HLX22 in combination with trastuzumab deruxtecan for HER2-low, hormone receptor-positive breast canc…